Archive

April 2025

Browsing

As precious metals surge on safe-haven demand, some gold mining companies are following suit. One standout is AngloGold Ashanti Ltd. (AU), which has been riding this upward momentum.

Recently, AU showed up among the Top 10 Large Cap category in the StockCharts Technical Rank (SCTR) Reports, indicating that it’s among the top large-cap stocks showing bullish technical strength across multiple timeframes and indicators.

FIGURE 1. SCREENSHOT OF SCTR REPORTS ON MONDAY MORNING. AU, which held the #6 spot at the time of the screenshot, had an ultra-bullish SCTR score of 99.3.

Unless you follow gold miners, you may not know much about AU. But here’s the skinny: AngloGold Ashanti Ltd. is a global independent mining company that’s incorporated in the UK but headquartered in Colorado, US. 

AU’s recent surge can be attributed to several factors, including rising gold prices, strong financials, recent strategic acquisitions, revised dividend policy, and general investor shift to safe havens.

If you’re unfamiliar with the stock, a good starting point is to compare its relative performance against its industry (Dow Jones Gold Mining Index or $DJUSPM) and spot gold price performance ($GOLD). The PerfChart below displays AU’s performance relative to the industry and gold’s price over the past year.

FIGURE 2. PERFCHARTS OF AU, DJ GOLD MINING INDEX, AND GOLD. AU began outperforming its overall industry and gold’s performance in late January.

AU and $DJUSPM have shown volatile, back-and-forth price action over the past 12 months, but AU began taking the lead in late January, surpassing both in comparative terms.

Now that you have a comparative view, let’s take a longer-term look at AU’s price action. Here’s a monthly chart spanning 20 years. Why so long? I had to go this far back to plot long-term resistance levels.

FIGURE 3. MONTHLY CHART OF AU. The stock just broke above a resistance range between $35 and $37, but there are plenty more technical headwinds above.

AU appears to be soaring at relatively high valuations and is running up against a major resistance range between $42 and $45. What adds weight to the long-term bullish case of AU’s current valuations is the rising Ichimoku Cloud, indicating a long-term uptrend projection (26 months) and a Relative Strength Index (RSI) reading that is rising but not quite overbought. Another thing to note, which is interesting, is that every time the RSI crossed 70, AU reversed to the downside. 

Despite this bullish projection, keep in mind that AU could still pull back—while remaining in a long-term uptrend—and decline to as low as $22.50 before rebounding. This level marks a key swing low and aligns with the top of the Ichimoku Cloud’s support range.

That gives us a long-term perspective. What about the near term? Might there be a favorable entry point for those looking to go long, or is AU technically overbought? 

Let’s shift over to a daily chart.

FIGURE 4. DAILY CHART OF AU. Pay attention to the most recent swing high and low.

The Gold Miners Bullish Percent Index (BPI) indicates strong bullish breadth as over 89% of gold mining stocks are rallying and triggering P&F buy signals. However, this can also indicate potential overbought levels, and the RSI supports this reading, as it, too, is over the 70 threshold (caveat: a stock can continue to rally for an extended period despite being overbought).

Volume-wise, note how accumulation preceded AU’s rally as far back as September when the Accumulation/Distribution Line (ADL) shown in orange began rising above AU’s price as if the smart money began accumulating the stock as it continued to decline before rebounding. AU currently trades above the ADL line, which could signal a near-term pullback. 

Pay attention to AU’s price relative to its most recent swing high (magenta dotted line) and swing low (blue dotted line). I plotted a ZigZag line to make these swing points clear. 

  • If AU pulls back, it may find support at the swing high near $33. What’s more important is that the stock price must hold above the swing low near $28 to sustain the current uptrend.
  • Expect resistance between $42 and $45 (as mentioned earlier when analyzing the monthly chart).

What Should You Do?

If you’re already in AU and not necessarily committed to the long term, consider tightening your stops or scaling out partial profits as the stock approaches the $42–$45 resistance zone. The RSI above 70 and elevated breadth readings across the gold mining sector suggest short-term overbought conditions, making a pullback likely—even within a broader uptrend. Watch for any bearish divergences or volume reversals, and use a bounce from $28 or $33 to potentially add to your position.

If you’re looking to enter, patience may pay. A retracement to the $33 support zone—or the swing low at $28 if sentiment reverses sharply—could offer a more favorable risk-reward entry. Keep in mind that a break below $28 would weaken the current technical structure and could open the door to a deeper correction, potentially down to $22.50.

For long-term investors, AU still holds promise. The rising monthly Ichimoku Cloud you saw in the monthly chart, strong accumulation trends, and outperformance vs. peers support a bullish longer-term case. But stay disciplined, and keep an ear on economic developments that may have a longer-term impact. Consider using a tiered entry approach rather than chasing highs.

In short, AU’s long-term momentum is intact, but don’t ignore the warning signs of a short-term cooldown. Stay tactical—ride the trend, but always protect your capital!

At the Close

While AU continues to ride the wave of bullish sentiment in the gold sector, a few of its technical indicators, appearing seemingly stretched, hint at a possible short-term breather. Long-term prospects remain intact, but near-term caution is warranted.


Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional.

Did you know you can generate more than a 5% monthly yield by utilizing an options strategy? 

In this educational video, Tony Zhang walks you through an income-generating options strategy using the OptionsPlay Strategy Center on StockCharts.com.

Learn how to select the right stocks, identify strike prices and expiration dates, analyze various outcomes, and manage your trades.

Armed with this knowledge, you will never want to miss out on the opportunity to generate income from your portfolio. 

This video premiered on April 1, 2025.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ.

After dropping to a low of 3,637.05 in October 2023, the index climbed to a nearly three year peak of 4,954.813 on September 19, 2024. While the index had pulled back to 4,243.7 as of March 31, 2025, further growth could be in store in the future.

According to a Towards Healthcare analyst report, the global biotech market is expected to grow at a compound annual growth rate of 12.5 percent from now to 2034, reaching a valuation of US$5.036 trillion.

Driving that growth will be favorable government policies, investment in the sector, increased demand for synthetic biology and a rise in chronic disorders such as cancer, heart disease and hypertension.

The top NASDAQ biotech stocks have seen sizeable share price increases over the past year. For those interested in investing in biotech companies, the best-performing small-cap biotech stocks are outlined below.

Data was gathered on March 31, 2025, using TradingView’s stock screener. Small-cap biotech stocks with market caps between US$50 million and US$500 million at that time were considered for this list.

1. Bright Minds Biosciences (NASDAQ:DRUG)

Company Profile

Year-over-year gain: 2,942.02 percent
Market cap: US$254.99 million
Share price: US$36.20

Bright Minds Biosciences is developing novel treatments for pain and neuropsychiatric disorders such as epilepsy, post-traumatic stress disorder and difficult-to-treat depression.The company’s platform includes serotonin agonists designed to provide powerful therapeutic benefits while minimizing side effects.

Bright Minds is currently in Phase 2 clinical trials for BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic absence epilepsy and developmental epileptic encephalopathy.

Bright Minds’ share price rocketed upward in the fourth quarter of last year, shooting up from US$2.49 to US$38.49 in one day on October 15. The company issued a press release at the time, stating it was ‘unaware of any material changes in the company’s operations’ that would have contributed to such a rally.

The outperformance appears to be related to the October 14 news that Danish pharma company H. Lundbeck was to acquire Longboard Pharma, a company developing a 5-HT2C receptor agonist, for US$60 per share.

A few days later, Bright Minds announced a non-brokered private placement of US$35 million, which sent shares up to US$47.21 on October 18.

That same month, the company shared its collaboration with Firefly Neuroscience (NASDAQ:AIFF) to use Firefly’s Brain Network Analytics technology platform to provide a full analysis of the electroencephalogram data from Bright Minds’ BMB-101 Phase 2 clinical trial. This follows the pair’s previous successful collaboration to analyze data from Bright Minds’ first-in-human Phase 1 study of BMB-101.

In March 2025, Bright Minds expanded its Scientific Advisory Board with the addition of five experts in epilepsy research.

Bright Minds’ share price reached US$55.77, its peak for the past year, on November 6.

2. Monopar Therapeutics (NASDAQ:MNPR)

Company Profile

Year-over-year gain: 924.54 percent
Market cap: US$220.3 million
Share price: US$36.10

Clinical-stage biotech Monopar Therapeutics’ main drug candidate is its late-stage ALXN-1840 for Wilson disease. Its pipeline also includes radiopharma programs such as Phase 1-stage MNPR-101-Zr for imaging advanced cancers, as well as Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers.

Shares in Monopar spiked by more than 600 percent on October 24, 2024, to US$32.66 following its news release detailing its exclusive worldwide licensing agreement with Alexion, AstraZeneca’s (NASDAQ:AZN) Rare Disease unit, for ALXN-1840, a drug candidate for Wilson disease that met its primary endpoints in its Phase 3 clinical trial. Going forward, Monopar will be responsible for all future global development and commercialization activities.

Further positive news flow in December continued to drive the company’s stock value. Early in the month, the company shared that the first patient was dosed with MNPR-101-Lu in its Phase 1a trial for the radiopharmaceutical. A few weeks later, Monopar announced the launch of a US$40 million concurrent public offering and private placement. After having fallen back to the US$22 range, shares in the company climbed to US$30.68 on December 17, 2024.

Positive sentiment in the company and the biotech market would later drive the stock up to its yearly high of US$51.89 on February 10, 2025. Monopar released its Q4 and full-year 2024 results on March 31.

3. Candel Therapeutics (NASDAQ:CADL)

Company Profile

Year-over-year gain: 268.3 percent
Market cap: US$262.39 million
Share price: US$5.64

Candel Therapeutics is a biotech company focused on developing oncology treatments. The company’s pipeline includes two clinical-stage multimodal biological immunotherapy platforms.

Candel’s lead product candidate, CAN-2409, is in a Phase 2 clinical trial in non-small cell lung cancer and borderline resectable pancreatic cancer, as well as Phase 2 and 3 trials for localized, non-metastatic prostate cancer.

The company had a number wins with the US Food and Drug Administration (FDA) in 2024. In February and May, respectively, Candel’s CAN-3110 received regulatory approval for fast-track designation and orphan drug designation for the treatment of recurrent high-grade glioma.

The agency also granted Candel orphan drug designation for CAN-2409 for the treatment of pancreatic cancer in April 2024. Positive interim data for the trial on pancreatic cancer released that month, sent the company’s share price spiking upward. It ultimately climbed to its 2024 high point of US$14.00 on May 15, 2024.

So far in 2025, Candel’s share price has traded as high as US$12.21 on February 20. In its January corporate update, the company shared its goals for the year, including aiming for Q4 for reporting overall survival data in patients with recurrent high-grade glioma from its ongoing phase 1b trial that is evaluating multiple doses of CAN-3110.

4. Tiziana Life Sciences (NASDAQ:TLSA)

Company Profile

Year-over-year gain: 154.76 percent
Market cap: US$119.51 million
Share price: US$1.08

Tiziana Life Sciences is a clinical-stage biopharma which is developing therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its pipeline of candidates is built on its patent drug delivery technology that provides a possible alternative to intravenous (IV) delivery. Tiziana’s lead candidate is intranasal foralumab, which it says is the only fully human anti-CD3 mAb currently in clinical development.

On May 31, 2024, shares in Tiziana broke above US$1 after a series of positive news flow for the company. This included positive clinical results from its intermediate sized Expanded Access Program for non-active secondary progressive multiple sclerosis patients, which demonstrated multiple improvements in foralumab-treated patients, as well as its submission of an orphan drug designation application to the FDA for intranasal foralumab for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS).

While Tiazana’s share price slid back down below US$1 per share by mid-June 2024, news that the FDA granted fast track designation to Tiziana intranasal foralumab for the treatment of na-SPMS gave it a much needed boost to the upside. By August 12, the stock’s value had risen to US$1.45 per share.

Tiziana Life Sciences shares reached a yearly peak of US$1.69 on March 7, 2025, after the company filed its investigational new drug application to the FDA for a phase 2 clinical trial in amyotrophic lateral sclerosis (ALS), which is supported by the ALS Association.

5. Benitec Biopharma (NASDAQ:BNTC)

Company Profile

Year-over-year gain: 149.71 percent
Market cap: US$331.43 million
Share price: US$13.01

California-based Benitec Biopharma is advancing novel genetic medicines via its proprietary “Silence and Replace” DNA-directed RNA interference platform. The company is currently focused on developing therapeutics for chronic and life-threatening conditions, including oculopharyngeal muscular dystrophy (OPMD).

Its drug candidate BB-301 was granted orphan drug designation by the FDA and the European Medicines Agency. Benitec is well funded to advance its BB-301 clinical development program through the end of 2025.

Benitec’s share price benefited from its first bump of the past year, after the company released its fiscal year Q3 2024 update in mid-May highlighting its achievements over the quarter. This included the closing of a US$40 million private placement. Benitec’s stock value hit US$10.47 per share on May 20, 2024.

Later in the fall, the company reported positive data from two patients with OPMD treated with low-dose BB-301 in phase 1b/2a study, showing the clinical trial is meeting key safety and efficacy endpoints. Shares hit another high of US$11.22 on October 17, 2024.

Benitec’s share price hit US$16.79, its highest yearly value to date, on March 20, 2025, a day after the company released positive interim clinical results for three patients with OPMD treated with BB-301 in phase 1b/2a study.

“The sixth and final Subject of Cohort 1 will be treated with BB-301 in the second calendar quarter of this year, and we are highly optimistic about the potential for continued benefit in Subjects enrolled in the ongoing clinical study,” said Jerel A. Banks, Benitec Executive Chairman and CEO.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

StrategX Elements Corp. (CSE: STGX) (‘StrategX’ or the ‘Company’) announces that Gary Wong has stepped down from his role as the Company’s Vice President of Exploration. While Gary is transitioning from this position, he will continue to contribute to other capacities, bringing his expertise and leadership to key projects. The Board would like to thank Gary for his efforts and contributions over the past two years.

About StrategX
StrategX is an exploration company focused on discovering critical metals in northern Canada. With projects on the East Arm of the Great Slave Lake (Northwest Territories) and the Melville Peninsula (Nunavut), the Company is pioneering new district-scale discoveries in these underexplored regions. By integrating historical data with modern exploration techniques, StrategX provides investors with a unique opportunity to participate in discovering essential metals crucial to electrification, global green energy, and supply chain security.

On Behalf of the Board of Directors

Darren G. Bahrey
CEO, President & Director

For further information, please contact:

StrategX Elements Corp.
info@strategXcorp.com
Phone: 604.379.5515

For further information about the Company, please visit our website at www.strategXcorp.com.

Neither the Canadian Securities Exchange nor its regulation services accept responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information
All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Not for distribution to United States newswire services or for dissemination in the United States.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247050

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

Stock Market News: UK Forecast and Technical Analysis

Today, the UK stock market saw the FTSE 250 increase by 195 points (0.9%) to 21,628, nearly matching the 1.2% increase in the FTSE 100, driven largely by gains in mining stocks. This positive momentum is creating a bullish sentiment in the market.

The two London indices are leading the European market this morning. The DAX is up 0.7% in Germany, followed by the FTSE MIB in Italy, the CAC 40 in France, and the IBEX 35 in Spain, all of which are up 0.4%, reinforcing the optimistic outlook across Europe.

The gain for the Euro Stoxx 600 is just under 1%. Risers include Just Eat Takeaway, rising 17%; TeamViewer, the software company and owner of Kenco, JD Peet.

Among the higher risers, Wickes Group PLC, one of the UK’s listed companies, has seen a 3.3% increase in revenue despite facing difficulties retaining customers for its custom kitchen, home office installation, and bathroom services.

In the first half, this segment’s revenues were destroyed by 17%, offsetting the 1% growth in revenue in its core retail offering.

GSK Shares Decline

GSK PLC, the drugmaker listed on the FTSE 100, raised its annual earnings and sales forecasts due to strong second-quarter performance from HIV and cancer treatments, but the stock is currently down 2.5%.

Core EPS profits are now expected to increase by 10-12% in 2024, up from the previous guidance of 8-10%. Meanwhile, the overall profits are expected to increase by 7-9%, compared to the earlier estimate of 5-7%.

Nonetheless, there were some omissions in the data: vaccination profit fell 9% short of expectations as shingles treatment Shingrix was a 20% disappointment as US sales plummeted 36%.

This is due to decreased demand and inventory reductions. However, it is important to note that international sales make up about 64% of total revenue.

General medicine, oncology, and HIV all performed better than anticipated.

GSK/GBX 5-Day Chart

Growth Expectation For FTSE 250

In the last five years, Greggs’ shares have increased by 40%, outpacing the FTSE 250 London stock. The company’s first-half (H1) results have given them an additional 5% boost.

The most recent data shows a 16% increase in profit before taxes and a 14% increase in sales.

However, despite these gains, projections indicate a minor decline in Greggs’ EPS for the full year 2024. However, the company’s first-half revenue increased by only 15%.

It is a basic diluted estimate that does not account for anomalies. However, it raises the possibility that projections are simply exaggerating the situation.

Thanks to these expenditures and a well-defined expansion plan, Greggs has produced substantial returns for its owners.

For the 2023 fiscal year, Greggs reported record yearly sales of £1.8 billion and a profit before taxes of £188.3 million.

The company also disclosed a significant capital investment program aimed at enhancing its manufacturing capacity and expanding its capacity to accommodate approximately 3,500 stores throughout the United Kingdom.

UK Stock Market Today: FTSE Stock Surge

Among the top risers in the FTSE, Antofagasta PLC and Rio Tinto have shown significant gains. Antofagasta PLC saw notable gains despite no specific news being released. Rio Tinto’s positive results, which included a 1.8% increase in first-half profit, contributed to a 1% rise in its shares and may have influenced the broader market.

More significantly, there are rumours that the Anglo-Australian miner Antofagasta is eyeing a major opportunity in the copper industry, further boosting investor confidence.

The Footsie has continued to rise, hitting a two-month peak of nearly 8,374 following a 1.2% increase. This is the highest value for the London standard since May 22nd, topping 8,368.

HSBC Makes a £3 Billion Buyback

Following a largely flat first half of the year, HSBC Holdings PLC announced an additional interim dividend and a £3 billion share buyback.

For the first half of 2024, the £0.10 per share dividend will equate to 20 cents, unchanged from the previous year. The share buyback is anticipated to be finished in three months.

The bank, with a focus on Asia, reported a first-half pre-tax profit of $21.6 billion, which was marginally lower than the same period last year, even though revenue increased 1% to $37.3 billion and certain “strategic transactions” had a net positive revenue impact of $0.2 billion.

The second quarter’s $16.5 billion in revenues exceeded analysts’ expectations, and the quarter’s $8.9 billion profit before taxes was significantly more than the $7.8 billion they had predicted.

Despite being lower than the 1.53% consensus estimate, the net interest margin improved from 1.7% to 1.62% a year ago due to an increase in the finance cost of average profit liabilities. These developments are significant for the stock market news UK, as they may influence investor sentiment and market trends.

FTSE 250 Share Price

  • Value: 21,572.34
  • Net Variation: 139.83
  • High/Low: 21,649.47 / 21,430.07
  • Previously closed price: 21,432.51
  • 52WK range: 16,783.09 – 21,432.51
  • Launch date: October 12th 1992
  • Constituents number: 250
  • Net MCap: 324,478
  • Dividend Yield: 3.35%
  • Average: 1,298
  • Largest: 4,059
  • Smallest: 81
  • Median: 1,085

FTSE 100 Share Price

  • Value: 8,390.33
  • Previous Close: 8,292.35
  • Open Price: 8,292.35
  • Day low: 8,235.55
  • Day High: 8,297.92
  • 52-week low: 7,215.76
  • 52-week high: 8,474.41

In summary, today’s gains on the stock market news UK are remarkable, as the FTSE 100 and FTSE 250 indices both saw an increase. Mining stocks, especially in the FTSE 100, have primarily driven these gains. Major indices have also increased throughout Europe, indicating an optimistic trend in the market.

While GSK continues to face difficulties even after increasing its earnings projections, Greggs has shown remarkable growth in both its stock price as well as profitability. Despite a little fluctuation in its profit margins, HSBC’s announcement of a significant share buyback and dividend demonstrates the strength of its financial position.

The post Stock Market News UK Update: FTSE 100 & 250 Rise appeared first on FinanceBrokerage.

Stock Market News: UK Forecast and Technical Analysis

Today, the UK stock market saw the FTSE 250 increase by 195 points (0.9%) to 21,628, nearly matching the 1.2% increase in the FTSE 100, driven largely by gains in mining stocks. This positive momentum is creating a bullish sentiment in the market.

The two London indices are leading the European market this morning. The DAX is up 0.7% in Germany, followed by the FTSE MIB in Italy, the CAC 40 in France, and the IBEX 35 in Spain, all of which are up 0.4%, reinforcing the optimistic outlook across Europe.

The gain for the Euro Stoxx 600 is just under 1%. Risers include Just Eat Takeaway, rising 17%; TeamViewer, the software company and owner of Kenco, JD Peet.

Among the higher risers, Wickes Group PLC, one of the UK’s listed companies, has seen a 3.3% increase in revenue despite facing difficulties retaining customers for its custom kitchen, home office installation, and bathroom services.

In the first half, this segment’s revenues were destroyed by 17%, offsetting the 1% growth in revenue in its core retail offering.

GSK Shares Decline

GSK PLC, the drugmaker listed on the FTSE 100, raised its annual earnings and sales forecasts due to strong second-quarter performance from HIV and cancer treatments, but the stock is currently down 2.5%.

Core EPS profits are now expected to increase by 10-12% in 2024, up from the previous guidance of 8-10%. Meanwhile, the overall profits are expected to increase by 7-9%, compared to the earlier estimate of 5-7%.

Nonetheless, there were some omissions in the data: vaccination profit fell 9% short of expectations as shingles treatment Shingrix was a 20% disappointment as US sales plummeted 36%.

This is due to decreased demand and inventory reductions. However, it is important to note that international sales make up about 64% of total revenue.

General medicine, oncology, and HIV all performed better than anticipated.

GSK/GBX 5-Day Chart

Growth Expectation For FTSE 250

In the last five years, Greggs’ shares have increased by 40%, outpacing the FTSE 250 London stock. The company’s first-half (H1) results have given them an additional 5% boost.

The most recent data shows a 16% increase in profit before taxes and a 14% increase in sales.

However, despite these gains, projections indicate a minor decline in Greggs’ EPS for the full year 2024. However, the company’s first-half revenue increased by only 15%.

It is a basic diluted estimate that does not account for anomalies. However, it raises the possibility that projections are simply exaggerating the situation.

Thanks to these expenditures and a well-defined expansion plan, Greggs has produced substantial returns for its owners.

For the 2023 fiscal year, Greggs reported record yearly sales of £1.8 billion and a profit before taxes of £188.3 million.

The company also disclosed a significant capital investment program aimed at enhancing its manufacturing capacity and expanding its capacity to accommodate approximately 3,500 stores throughout the United Kingdom.

UK Stock Market Today: FTSE Stock Surge

Among the top risers in the FTSE, Antofagasta PLC and Rio Tinto have shown significant gains. Antofagasta PLC saw notable gains despite no specific news being released. Rio Tinto’s positive results, which included a 1.8% increase in first-half profit, contributed to a 1% rise in its shares and may have influenced the broader market.

More significantly, there are rumours that the Anglo-Australian miner Antofagasta is eyeing a major opportunity in the copper industry, further boosting investor confidence.

The Footsie has continued to rise, hitting a two-month peak of nearly 8,374 following a 1.2% increase. This is the highest value for the London standard since May 22nd, topping 8,368.

HSBC Makes a £3 Billion Buyback

Following a largely flat first half of the year, HSBC Holdings PLC announced an additional interim dividend and a £3 billion share buyback.

For the first half of 2024, the £0.10 per share dividend will equate to 20 cents, unchanged from the previous year. The share buyback is anticipated to be finished in three months.

The bank, with a focus on Asia, reported a first-half pre-tax profit of $21.6 billion, which was marginally lower than the same period last year, even though revenue increased 1% to $37.3 billion and certain “strategic transactions” had a net positive revenue impact of $0.2 billion.

The second quarter’s $16.5 billion in revenues exceeded analysts’ expectations, and the quarter’s $8.9 billion profit before taxes was significantly more than the $7.8 billion they had predicted.

Despite being lower than the 1.53% consensus estimate, the net interest margin improved from 1.7% to 1.62% a year ago due to an increase in the finance cost of average profit liabilities. These developments are significant for the stock market news UK, as they may influence investor sentiment and market trends.

FTSE 250 Share Price

  • Value: 21,572.34
  • Net Variation: 139.83
  • High/Low: 21,649.47 / 21,430.07
  • Previously closed price: 21,432.51
  • 52WK range: 16,783.09 – 21,432.51
  • Launch date: October 12th 1992
  • Constituents number: 250
  • Net MCap: 324,478
  • Dividend Yield: 3.35%
  • Average: 1,298
  • Largest: 4,059
  • Smallest: 81
  • Median: 1,085

FTSE 100 Share Price

  • Value: 8,390.33
  • Previous Close: 8,292.35
  • Open Price: 8,292.35
  • Day low: 8,235.55
  • Day High: 8,297.92
  • 52-week low: 7,215.76
  • 52-week high: 8,474.41

In summary, today’s gains on the stock market news UK are remarkable, as the FTSE 100 and FTSE 250 indices both saw an increase. Mining stocks, especially in the FTSE 100, have primarily driven these gains. Major indices have also increased throughout Europe, indicating an optimistic trend in the market.

While GSK continues to face difficulties even after increasing its earnings projections, Greggs has shown remarkable growth in both its stock price as well as profitability. Despite a little fluctuation in its profit margins, HSBC’s announcement of a significant share buyback and dividend demonstrates the strength of its financial position.

The post Stock Market News UK Update: FTSE 100 & 250 Rise appeared first on FinanceBrokerage.

Restaurant chain Hooters of America filed for bankruptcy protection in Texas on Monday, seeking to address its $376 million debt by selling all of its company-owned restaurants to a franchise group backed by the company’s founders.

Hooters, like other casual dining restaurants, has struggled in recent years due to inflation, the high costs of labor and food and declining spending by cash-strapped American consumers. The company currently directly owns and operates 151 locations, with another 154 restaurants operated by franchisees, primarily in the United States.

The privately-owned company, which shares a private equity owner with recently-bankrupt TGI Fridays, intends to sell all corporate-owned locations to a buyer group comprised of two existing Hooters franchisees, who operate 30 high-performing Hooters locations in the U.S., mainly in Florida and Illinois.

Hooters did not disclose the purchase price of the transaction, which must be approved by a U.S. bankruptcy judge before it becomes final.

Founded in 1983, Hooters became famous for its chicken wings and its servers’ uniform of orange shorts and low-cut tank tops.

The buyer group is backed by some of Hooters’ original founders, and it pledged to take Hooters “back to its roots.”

“With over 30 years of hands-on experience across the Hooters ecosystem, we have a profound understanding of our customers and what it takes to not only meet, but consistently exceed their expectations,” said Neil Kiefer, a member of the buyer group and the current CEO of the original Hooters’ location in Clearwater, Florida.

Hooters said it expects to complete the deal and emerge from bankruptcy in three to four months. The company has lined up about $35 million in financing from its existing lender group to complete the bankruptcy transaction.

Casual dining restaurants have been hammered by rising costs in 2024, with well-known chains like TGI Fridays, Red Lobster, Bucca di Beppo, and Rubio’s Coastal Grill all filing for bankruptcy last year.

Restaurant prices have risen about 30% in the last 5 years, outpacing consumer prices overall, according to the Federal Reserve Bank of St. Louis.

This post appeared first on NBC NEWS

Meta’s head of artificial intelligence research announced Tuesday that she will be leaving the company. 

Joelle Pineau, the company’s vice president of AI research, announced her departure in a LinkedIn post, saying her last day at the social media company will be May 30. 

Her departure comes at a challenging time for Meta. CEO Mark Zuckerberg has made AI a top priority, investing billions of dollars in an effort to become the market leader ahead of rivals like OpenAI and Google.

Zuckerberg has said that it is his goal for Meta to build an AI assistant with more than 1 billion users and artificial general intelligence, which is a term used to describe computers that can think and take actions comparable to humans.

“As the world undergoes significant change, as the race for AI accelerates, and as Meta prepares for its next chapter, it is time to create space for others to pursue the work,” Pineau wrote. “I will be cheering from the sidelines, knowing that you have all the ingredients needed to build the best AI systems in the world, and to responsibly bring them into the lives of billions of people.”

Pineau was one of Meta’s top AI researchers and led the company’s fundamental AI research unit, or FAIR, since 2023. There, she oversaw the company’s cutting-edge computer science-related studies, some of which are eventually incorporated into the company’s core apps. 

She joined the company in 2017 to lead Meta’s Montreal AI research lab. Pineau is also a computer science professor at McGill University, where she is a co-director of its reasoning and learning lab.

Some of the projects Pineau helped oversee include Meta’s open-source Llama family of AI models and other technologies like the PyTorch software for AI developers.

Pineau’s departure announcement comes a few weeks ahead of Meta’s LlamaCon AI conference on April 29. There, the company is expected to detail its latest version of Llama. Meta Chief Product Officer Chris Cox, to whom Pineau reported to, said in March that Llama 4 will help power AI agents, the latest craze in generative AI. The company is also expected to announce a standalone app for its Meta AI chatbot, CNBC reported in February. 

“We thank Joelle for her leadership of FAIR,” a Meta spokesperson said in a statement. “She’s been an important voice for Open Source and helped push breakthroughs to advance our products and the science behind them.” 

Pineau did not reveal her next role but said she “will be taking some time to observe and to reflect, before jumping into a new adventure.”

This post appeared first on NBC NEWS

Thank You!

I’ve been writing at StockCharts.com for nearly 20 years now and many of you have supported my company, EarningsBeats.com, and I certainly want to show my appreciation for all of your loyalty. I believe we’re at a major crossroads in the stock market as the S&P 500 tests the recent price low from earlier in March. I called for a 2025 correction at our MarketVision 2025 event on January 4, 2025, to start the year and now it’s a reality. We decided at that time to add quarterly updates to our MarketVision series and our first update (Q1 update) is being held today at 5:30pm ET. I would like to invite everyone to join EarningsBeats.com and join me later today. We will record the event for those who cannot attend live.

Even if you decide not to join as an EB.com member, I do want to provide you my latest Weekly Market Report that we send out to our members at the start of every week, in addition to our Daily Market Report, which is published Tuesdays through Fridays.

I hope you enjoy!

MarketVision 2025 Q1 Update

Join us for our MarketVision 2025 Q1 update at 5:30pm ET today. This is an exclusive event for our annual members. If you’re already an annual member, room instructions will be sent to you in a separate email.

Not yet an annual member? Save $200 on membership TODAY ONLY. This offer will expire at the start of today’s event, so CLICK HERE for more information and details!

If you recall, on Saturday, January 4, 2025, I provided my annual forecast, which included my belief that we’d see a 10% on the S&P 500. That 10% correction is now in the rear view mirror, but what will happen from here? A lot has changed and we must remain objective as to where we might go. I’ll provide you my latest thoughts on this during today’s event.

I hope to see you at 5:30pm ET!

ChartLists Updated

The following ChartLists were updated over the weekend:

  • Strong Earnings (SECL)
  • Strong Future Earnings (SFECL)
  • Raised Guidance (RGCL)

These ChartLists are available to download into your StockCharts Extra or Pro account, if you have a StockCharts membership. Otherwise, we can send you an Excel file with the stocks included in these ChartLists in order to download them into other platforms. If you have any questions, please reach out to us at “support@earningsbeats.com”.

Weekly Market Recap

Major Indices

Sectors

Top 10 Industries Last Week

Bottom 10 Industries Last Week

Top 10 Stocks – S&P 500/NASDAQ 100

Bottom 10 Stocks – S&P 500/NASDAQ 100

Big Picture

The monthly PPO and monthly RSI are both moving lower now, but remember, we have not ever seen a secular bear market that did not coincide with a negative monthly PPO and a monthly RSI below 40. I believe we’ll see this market weakness end LONG BEFORE we see either of those technical developments on the above chart.

Sustainability Ratios

Here’s the latest look at our key intraday ratios as we follow where the money is traveling on an INTRADAY basis (ignoring gaps):

QQQ:SPY

Relative weakness in the QQQ:SPY, including and excluding gaps, has turned back down in a big way. That’s not what you want to see from a bullish perspective. We must remain on guard for potential short-term downside action, especially if key closing price support at 5521 fails on the S&P 500.

IWM:QQQ

Small caps (IWM) seem to be performing better than the aggressive, Mag 7 led NASDAQ 100, but that’s not saying a lot when you look at the IWM’s absolute performance in the bottom panel. Perhaps we’ll still get the small-cap run that we’ve been looking for over the past year, but it’ll likely need to be accompanied by a much more dovish Fed and with the short-term fed funds rate falling.

XLY:XLP

I mentioned last week that this chart was the biggest positive of the prior week. I suppose I now need to say it’s the biggest negative of last week because it did an abrupt about-face. It appears that the options expiration and oversold bounce we enjoyed for over a week have ended. We haven’t broken back to new relative lows, which would obviously be bearish, but we did back a lot of ground that we had previously made up. The XLY:XLP ratio is one of the most important in the stock market, as far as I’m concerned. Watching it turn back down is not a great feeling, and a new upcoming relative low would only make it worse.

Sentiment

5-day SMA ($CPCE)

Sentiment indicators are contrarian indicators. When they show extreme bullishness, we need to be a bit cautious and when they show extreme pessimism, it could be time to become much more aggressive. Major market bottoms are carved out when pessimism is at its absolute highest level.

When an elevated Cboe Volatility Index ($VIX) sends a signal that we could see pain ahead, which is exactly the message sent recently as the VIX approached 30, I usually turn my attention to a rising 5-day SMA of the equity-only put-call ratio ($CPCE) to help identify market bottoms. Once the stock market turns emotionally and begins to show fear and panic, key price support levels tend to fail, and a high reading in the VIX, combined with a huge reversal on the S&P 500 (think capitulation), usually are typical ingredients to establish a key bottom.

We’re finally starting to see some higher daily CPCE readings, which suggests that options traders are growing much more nervous, and that’s a good thing if we’re going to try to carve out a meaningful market bottom. The last four days have seen readings of 0.65, 0.71, 0.72, and 0.68. That’s not quite high enough to grow more convinced of an impending bottom in stocks, but it’s light years better than what we’ve seen during any other recent market selloffs.

253-day SMA ($CPCE)

We’re coming off an extended run higher in the benchmark S&P 500, where we topped on February 19. The long-term picture with sentiment is much different than it was 1.5 to 2 years ago. Back then, everyone was bearish, leading to an important market bottom and a subsequent rally to new all-time highs. We could use more bearishness in options to set us up for another rally to all-time highs. Based on this chart, we’re not there yet.

Volatility ($VIX)

Here’s the current view of the VIX:

There was one key development in the VIX. From studying the VIX long-term, whenever a top has been reached, and significant selling ensues, the VIX typically spikes into the 20s or 30s before we see some sort of a rebound, like the one we saw recently. When these bounces have been part of bear market counter rallies, the VIX has never dropped below the 16-17 support range. So for those looking for this current correction to morph into a bear market, the hope is absolutely alive and kicking. My interpretation is that bear markets require a certain level of uncertainty and fear. The VIX remaining above that 16-17 level is our proof that the market environment for further selling still exists. In the above chart, the VIX fell to 17 and then quickly reversed and today hit a high of 24.80.

Based on this one signal alone, I cannot rule out further selling ahead and a possible cyclical bear market, as opposed to the much more palatable correction.

Long-Term Trade Setup

Since beginning this Weekly Market Report in September 2023, I’ve discussed the long-term trade candidates below that I really like. Generally, these stocks have excellent long-term track records, and many pay nice dividends that mostly grow every year. Only in specific cases (exceptions) would I consider a long-term entry into a stock that has a poor or limited long-term track record and/or pays no dividends. Below is a quick recap of how I viewed their long-term technical conditions as of one week ago:

  • JPM – nice bounce off the recent 50-week SMA test
  • BA – up more than 20% in less than 2 weeks; 190-192 likely to prove a difficult level to pierce
  • FFIV – 20-week EMA test successful thus far
  • MA – another with a 20-week SMA test holding
  • GS – 10% bounce off its recent 50-week SMA test
  • FDX – lengthy four-month decline finally tested, and held, price support near 220
  • AAPL – weakness has not cleared best price support on the chart at 200 or just below
  • CHRW – testing significant 95 level, where both price and 50-day SMA support reside
  • JBHT – has fallen slightly beneath MAJOR support around 150
  • STX – 85 support continues to hold
  • HSY – did it just print a reverse right shoulder bottom on its weekly chart?
  • DIS – trendless as weekly moving averages are not providing support or resistance
  • MSCI – 3-year uptrend remains in play, though it’s been in a rough 6-7 week stretch
  • SBUX – first critical price test at all-time high near 116 failed miserably; support resides at 85
  • KRE – looking to establish short-term bottom at 55, with 2-year uptrend intact
  • ED – showing strength in March for 9th time in 10 years, moving to new all-time high
  • AJG – continues one of most consistent and dependable uptrends, trading just below all-time high
  • NSC – testing 230 price support as transportation woes continue
  • RHI – has broken recent price support in upper-50s; searching for new bottom with 4.4% dividend yield
  • ADM – struggled again at 20-week EMA, 45 represents a significant test of long-term uptrend
  • BG – approaching 4-year price support at 65 after failed test of declining 20-week EMA
  • CVS – bottom now seems light years away as CVS trades nearly 1-year high
  • IPG – how long can it hold onto multi-year price support at 26?
  • HRL – still bound between price support at 27.50 and 20-week EMA resistance at 30.15
  • DE – still trending above its rising 20-week EMA

Keep in mind that our Weekly Market Reports favor those who are more interested in the long-term market picture. Therefore, the list of stocks above are stocks that we believe are safer (but nothing is ever 100% safe) to own with the long-term in mind. Nearly everything else we do at EarningsBeats.com favors short-term momentum trading, so I wanted to explain what we’re doing with this list and why it’s different.

Also, please keep in mind that I’m not a Registered Investment Advisor (and neither is EarningsBeats.com nor any of its employees) and am only providing (mostly) what I believe to be solid dividend-paying stocks for the long term. Companies periodically go through adjustments, new competition, restructuring, management changes, etc. that can have detrimental long-term impacts. Neither the stock price nor the dividend is ever guaranteed. I simply point out interesting stock candidates for longer-term investors. Do your due diligence and please consult with your financial advisor before making any purchases or sales of securities.

Looking Ahead

Upcoming Earnings

Very few companies will report quarterly results until mid-April. The following list of companies is NOT a list of all companies scheduled to report quarterly earnings, however, just key reports, so please be sure to check for earnings dates of any companies that you own. Any company in BOLD represents a stock in one of our portfolios and the amount in parenthesis represents the market capitalization of each company listed:

  • Monday: None
  • Tuesday: None
  • Wednesday: None
  • Thursday: None
  • Friday: None

Key Economic Reports

  • Monday: March Chicago PMI
  • Tuesday: March PMI manufacturing, March ISM manufacturing, February construction spending, Feb JOLTS
  • Wednesday: March ADP employment report, February factory orders
  • Thursday: Initial jobless claims, March ISM services
  • Friday: March nonfarm payrolls, unemployment rate, average hourly earnings

Historical Data

I’m a true stock market historian. I am absolutely PASSIONATE about studying stock market history to provide us more clues about likely stock market direction and potential sectors/industries/stocks to trade. While I don’t use history as a primary indicator, I’m always very aware of it as a secondary indicator. I love it when history lines up with my technical signals, providing me with much more confidence to make particular trades.

Below you’ll find the next two weeks of historical data and tendencies across the three key indices that I follow most closely:

S&P 500 (since 1950)

  • Mar 31: -7.16%
  • Apr 1: +67.49%
  • Apr 2: +17.08%
  • Apr 3: -0.40%
  • Apr 4: -17.99%
  • Apr 5: +68.25%
  • Apr 6: +45.38%
  • Apr 7: -48.59%
  • Apr 8: +62.64%
  • Apr 9: +60.32%
  • Apr 10: +47.37%
  • Apr 11: -29.33%
  • Apr 12: +63.88%
  • Apr 13: -21.35%

NASDAQ (since 1971)

  • Mar 31: +39.81%
  • Apr 1: +83.56%
  • Apr 2: +18.47%
  • Apr 3: -86.48%
  • Apr 4: -70.46%
  • Apr 5: +112.55%
  • Apr 6: +26.71%
  • Apr 7: -38.23%
  • Apr 8: +44.64%
  • Apr 9: +60.64%
  • Apr 10: +47.74%
  • Apr 11: -51.08%
  • Apr 12: +33.04%
  • Apr 13: -0.08%

Russell 2000 (since 1987)

  • Mar 31: +78.83%
  • Apr 1: +27.91%
  • Apr 2: +18.08%
  • Apr 3: -113.26%
  • Apr 4: -75.19%
  • Apr 5: +101.16
  • Apr 6: +51.29%
  • Apr 7: -90.50%
  • Apr 8: +59.63%
  • Apr 9: +137.22%
  • Apr 10: +5.20%
  • Apr 11: -80.66%
  • Apr 12: +45.00%
  • Apr 13: -37.09%

The S&P 500 data dates back to 1950, while the NASDAQ and Russell 2000 information date back to 1971 and 1987, respectively.

Final Thoughts

As I mentioned last week, I’m sticking with my belief that the S&P 500 ultimate low in 2025 will mark a correction (less than 20% drop) rather than a bear market (more than 20% drop). But a bear market cannot be ruled out. Honestly, I think sentiment ($CPCE) must turn much more bearish. This morning, we had another gap down and early selling and this is beginning to take a toll on options traders as they’re now starting to grow more bearish. As an example, check out this morning’s equity-only put call ratio at Cboe.com:

These Cboe.com readings are very high and show a definite shift in sentiment among options traders. Intense selling pressure and lots of equity puts being traded, relative to equity calls, help to mark bottoms.

Here are a few things to consider in the week ahead:

  • The Rebound. It ended rather quickly last week. I mentioned it’s a rebound until it isn’t. We moved right up to 5782 price resistance on the S&P 500 and the bears took over.
  • The Roll Over. We’re now in rollover mode, but the S&P 500 quickly lost 300 points from 5782 to today’s early low of 5488, which tested key short-term price support from March 13, where we printed a low close of 5521. Can the bulls hold onto support?
  • Nonfarm payrolls. This report will be out on Friday morning and current expectations are for March jobs (131,000) to fall below the February number of 151,000. Also, unemployment is expected to move up slightly from 4.1% to 4.2%. Should any of these numbers come in weaker than expected, the Fed could be in a box and Wall Street could sense it by selling off hard.
  • Sentiment. As I’ve said before, once the VIX moves beyond 20, not many good things happen to stocks. Selling can escalate very quickly as market makers go “on vacation.” Many times, we don’t find a bottom until retail options traders begin buying puts hand over fist. That could be underway right now.
  • Rotation. Rotation led us to where we are now, we need to continue to monitor where the money is going.
  • Seasonality. There is one real positive here. We’re about to move from the “2nd half of Q1”, which historically has produced annualized returns of +5.05% (4 percentage points BELOW the average annual S&P 500 return of +9%), to the “1st half of Q2”, which historically has produced annualized returns of 13.08% (4 percentage points ABOVE the average annual S&P 500 return of +9%). This half-quarter trails only the 1st and 2nd halves of Q4 in terms of half-quarter performance.
  • Manipulation. Yep, it’s starting again, just like it did during 2022’s cyclical bear market, which ultimately marked a critical S&P 500 bottom. We’ve done a ton of research on intraday trading behavior on our key indices, and many market-moving stocks like the Mag 7. Our Excel spreadsheet has been made available to all ANNUAL members, where you can see the manipulation for yourself.

Happy trading!

Tom

You may not know it, but all of the Magnificent Seven stocks are in bear markets. Given they are such an integral part of the major indexes, we have to believe that the market will follow suit and continue lower in its own bear market. The SP500 is in correction territory already.

Given the decline in the market it was especially interesting to see what the condition of the market is right now. Carl gave us his overview of market conditions with a review of the DP Signal Tables and key market indicators.

In the question period of the show, Carl and Erin gave their opinions on NVDA and Bonds in particular.

Erin caught us up on Sector Rotation where we are seeing clear patterns of market rotation from aggressive sectors to defensive sectors. She took a deep dive into key sectors to include Energy and Utilities.

Erin finished up the program taking viewer symbol requests to look for long candidates and determine key support and resistance levels.

01:02 Market Overview

13:45 Magnificent Seven

20:28 Questions

31:00 Sector Rotation & Under the Hood Sector Charts

39:00 Symbol Requests

Don’t forget! We are running a 2-week free trial on any of our products. Just use coupon code: DPTRIAL2 at checkout. Subscribe here: https://www.decisionpoint.com/products.html

You can join us in the free DecisionPoint Trading Room on Mondays at Noon ET! Just register once here: https://zoom.us/webinar/register/WN_D6iAp-C1S6SebVpQIYcC6g#/registration


The DP Alert: Your First Stop to a Great Trade!

Before you trade any stock or ETF, you need to know the trend and condition of the market. The DP Alert gives you all you need to know with an executive summary of the market’s current trend and condition. It not only covers the market! We look at Bitcoin, Yields, Bonds, Gold, the Dollar, Gold Miners and Crude Oil! Only $50/month! Or, use our free trial to try it out for two weeks using coupon code: DPTRIAL2. Click HERE to subscribe NOW!


Learn more about DecisionPoint.com:


Watch the latest episode of the DecisionPointTrading Room on DP’s YouTube channel here!


Try us out for two weeks with a trial subscription!

Use coupon code: DPTRIAL2 Subscribe HERE!


Technical Analysis is a windsock, not a crystal ball. –Carl Swenlin


(c) Copyright 2025 DecisionPoint.com


Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional. Any opinions expressed herein are solely those of the author, and do not in any way represent the views or opinions of any other person or entity.

DecisionPoint is not a registered investment advisor. Investment and trading decisions are solely your responsibility. DecisionPoint newsletters, blogs or website materials should NOT be interpreted as a recommendation or solicitation to buy or sell any security or to take any specific action.


Helpful DecisionPoint Links:

Trend Models

Price Momentum Oscillator (PMO)

On Balance Volume

Swenlin Trading Oscillators (STO-B and STO-V)

ITBM and ITVM

SCTR Ranking

Bear Market Rules